Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) EV-to-EBIT : 11.26 (As of Apr. 28, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Clinuvel Pharmaceuticals's Enterprise Value is $375.53 Mil. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $33.35 Mil. Therefore, Clinuvel Pharmaceuticals's EV-to-EBIT for today is 11.26.

The historical rank and industry rank for Clinuvel Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

CLVLF' s EV-to-EBIT Range Over the Past 10 Years
Min: -96.17 Med: 24.15 Max: 154.19
Current: 11.2

During the past 13 years, the highest EV-to-EBIT of Clinuvel Pharmaceuticals was 154.19. The lowest was -96.17. And the median was 24.15.

CLVLF's EV-to-EBIT is ranked worse than
55.53% of 443 companies
in the Biotechnology industry
Industry Median: 8.19 vs CLVLF: 11.20

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Clinuvel Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $411.29 Mil. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $33.35 Mil. Clinuvel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 8.11%.

Clinuvel Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Clinuvel Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals EV-to-EBIT Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

87.96

91.32

52.52

16.76

14.92

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-	16.76	-	14.92	-

Competitive Comparison of Clinuvel Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's EV-to-EBIT falls into.

Clinuvel Pharmaceuticals EV-to-EBIT Calculation

Clinuvel Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	375.527	/	33.345
	=	11.26

Clinuvel Pharmaceuticals's current Enterprise Value is $375.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $33.35 Mil.

Clinuvel Pharmaceuticals (OTCPK:CLVLF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Clinuvel Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	33.345	/	411.289196
	=	8.11 %

Clinuvel Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $411.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Clinuvel Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $33.35 Mil.

Clinuvel Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.